WT5”BZ]To evaluate effects of HBsAg-iRNA and Ara-AMP combined with thymus peptide therapy of chronic hepatitis B, this was randomized trial 136 patients (HBeAg and HBV-DNA positive) were randomized into three groups, group 1 was deected with HBsAg-iRNA 2mg IM q o d 3 months, Ara-AMP 10mg/Kg, IM q d for 5 days then 5kg/Kg IM q d for 23 days and combined with thyus peptide 10 mg IM q d for 30 days Group 2 thedrugs and dosage same to group 1, but the thymus peptide IM for 90 days Group 3was control by The end of therapy (3MO) , those group 1, 2, 3 the ALT turn to recover (93 85%;93 35%;47 6%) , P<0 05, HBeAg turn to negative (32 7%;37 8%;9 4%) , HBV-DNA turn to negative (34 0%;40 0%;2 4%) , P<0 05 Follow up for one year Those group 1, 2, 3, ALT turn to recover (85 7%;91 0%;50 0%) , P<0 05 HBeAg turn to negative (30 6%;33 3%;11 9%) , P<0 05 HBV-DNA turn to negative (30 6%;35 6%;11 9%) , P<0 05 Combined with these three drags to treatment chronic hepatitis B are effective [WT5”HZ]
DownLoad: